Inventor · disambiguated record
Benoit Van Den Eynde
Also filed as: VAN DEN EYNDE BENOIT · VAN DEN EYNDE BENOIT J · Van Den Eynde Benoît
34 granted patents·12 pending applications·667 citations·filing 1991–2021
97Inventor score
Files withLUDWIG INST CANCER RES31UNIV CATHOLIQUE LOUVAIN5DADAGLIO GILLES3LUDWIG INST FOR CANCER RES LTD2MA WENBIN2
Top patents by PatentIndex Score
46 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0289US5648226AIsolated peptides derived from tumor rejection antigens, and their useLUDWIG INST CANCER RES·Filed 1995·Granted Jul 15, 1997·72 cites·6 claims
- 0382US5939526AIsolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Aug 17, 1999·55 cites·3 claims
- 0481US7495074B2Isolated proteins MAGE-4 and MAGE-41LUDWIG INST CANCER RES·Filed 2005·Granted Feb 24, 2009·1 cites·8 claims
- 0580US6235525B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereofLUDWIG INST CANCER RES·Filed 1993·Granted May 22, 2001·27 cites·10 claims
- 0678US5610013AMethod for diagnosing a disorder by determining expression of gage tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 11, 1997·40 cites·37 claims
- 0778US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 0876US7547517B2MAGE-C2 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2003·Granted Jun 16, 2009·3 cites·6 claims
- 0975US6939707B2Isolated nucleic acid molecules which encode GAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 2001·Granted Sep 6, 2005·3 cites·9 claims
- 1075US6897288B1Mage-A12 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted May 24, 2005·7 cites·16 claims
- 1175US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 1274US7199231B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Apr 3, 2007·3 cites·12 claims
- 1374US6946289B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Sep 20, 2005·1 cites·6 claims
- 1472US6552180B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Apr 22, 2003·1 cites·25 claims
- 1572US5695994AIsolated cytolytic T cells specific for complexes of MAGE related peptides and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 9, 1997·20 cites·6 claims
- 1671US9410139B2Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigensDADAGLIO GILLES·Filed 2008·Granted Aug 9, 2016·3 cites·5 claims
- 1770US6025474AIsolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereofLUDWIG INST CANCER RES·Filed 1997·Granted Feb 15, 2000·21 cites·2 claims
- 1869US8143011B2MAGE-C2 antigenic peptides and uses thereofMA WENBIN·Filed 2011·Granted Mar 27, 2012·1 cites·6 claims
- 1965US5858689AIsolated peptides derived from the gage tumor rejection antigen precursor and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Jan 12, 1999·15 cites·4 claims
- 2061US6069001AIsolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted May 30, 2000·14 cites·13 claims
- 2161US2007219349A1Isolated GAGE-7B and 8 proteinsBACKER OLIVIER D·Filed 2007·Application pending·0 cites
- 2260US6013481AIsolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Jan 11, 2000·21 cites·14 claims
- 2360US2011159017A1Trytophan catabolism in cancer treatment and diagnosisLUDWIG INST FOR CANCER RES LTD·Filed 2009·Application pending·0 cites
- 2459US7572885B2Isolated GAGE-7B and 8 proteinsLUDWIG INST CANCER RES·Filed 2002·Granted Aug 11, 2009·0 cites·13 claims
- 2557US6222012B1Isolated nonapeptides presented by HLA molecules, and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Apr 24, 2001·10 cites·7 claims
- 2657US2009233315A1MAGE-C2 antigenic peptides and uses thereforMA WENBIN·Filed 2009·Application pending·0 cites
- 2756US2011112282A1Ido inhibitors and therapeutic uses thereofROEHRIG UTE·Filed 2009·Application pending·0 cites
- 2853US2021244814A1Combination of metformin and cyclophosphamide as an adjuvant in cancer immunotherapyUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 2952US6379901B1Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Apr 30, 2002·12 cites·2 claims
- 3052US2023149360A1Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disordersUNIV CATHOLIQUE LOUVAIN·Filed 2021·Application pending·0 cites
- 3151US6599699B1Methods for diagnosing a disorder by assaying for MAGE-3LUDWIG INST CANCER RES·Filed 1999·Granted Jul 29, 2003·4 cites·4 claims
- 3251US2010273671A1Method for the determination and the classification of rheumatic conditionsUNIV CATHOLIQUE LOUVAIN·Filed 2008·Application pending·0 cites
- 3351US2021353749A1Guanabenz as an adjuvant for immunotherapyUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 3451US2023165836A1Alpha-2 adrenergic receptor agonists for the treatment of cancerUNIV CATHOLIQUE LOUVAIN·Filed 2021·Application pending·0 cites
- 3550US12180501B2Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancerLUDWIG INST FOR CANCER RES LTD·Filed 2019·Granted Dec 31, 2024·0 cites·28 claims
- 3650US2005271679A1Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigensDADAGLIO GILLES·Filed 2004·Application pending·0 cites
- 3750US2014227323A1Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigensDADAGLIO GILLES·Filed 2013·Application pending·0 cites
- 3846US2010310594A1Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigensINST PASTEUR A CORP OF FRANCE·Filed 2010·Application pending·0 cites
- 3944US5512437AMethod for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3LUDWIG INST CANCER RES·Filed 1994·Granted Apr 30, 1996·11 cites·11 claims
- 4037US6565857B1Methods for treating a disorder by using Mage-3 or Mage-3 related materialsLUDWIG INST CANCER RES·Filed 1999·Granted May 20, 2003·1 cites·12 claims
- 4135US6509172B1Isolated, truncated nucleic acid which are members of the gage, and uses thereofLUDWIG INST CANCER RES·Filed 1998·Granted Jan 21, 2003·1 cites·28 claims
- 4233US6667037B1Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereofLUDWIG INST CANCER RES·Filed 1998·Granted Dec 23, 2003·3 cites·4 claims
- 4332US7923534B1Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1997·Granted Apr 12, 2011·0 cites·3 claims
- 4431USRE40089ENucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1996·Granted Feb 19, 2008·0 cites·25 claims
- 4529US6087441AStructurally modified peptides that are resistant to peptidase degradationLUDWIG INST CANCER RES·Filed 1997·Granted Jul 11, 2000·2 cites·23 claims
- 4625US6623740B1Structurally modified peptides that are resistant to peptidase degradationLUDWIG INST CANCER RES·Filed 1998·Granted Sep 23, 2003·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Benoit Van Den Eynde files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →